BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 03/31/2015 234,238 188,777 415.25 372
Institutional Ownership now stands at 7.23%
more institutions have yet to be updated
Amy Babcock Schutt
Amy Babcock Schutt who is related to our CEO babcock is a
Ethicon Endo-Surgery, Johnson & Johnson
Executive Account Manager · 2005 to present · Los Angeles, California
x54389DOTweeblyDOTcom / 617-open-letter-to-ftc-re-the-street-inc-possible-nationwide-advertising-fraud-and-deceptionDOThtml
this is not retail 50 share buy because it would be stupid to buy 50 shares @ 1.83 pay the 9.99 trade price and more for ah buy. this was MM
BACKGROUND: The feasibility and efficacy of re-irradiation using contemporary radiation techniques to treat recurrent head and neck cancer have been demonstrated, but the role of brachytherapy is unclear. Here, we describe the use of cesium (Cs)-131 brachytherapy with concurrent salvage surgery in 18 patients.
MATERIALS AND METHODS: Eligible patients underwent maximal gross resection of the tumor with implantation of Cs-131 brachytherapy seeds, delivering a minimum dose of 80 Gy to the tumor bed. Rates of overall survival (OS), locoregional progression-free survival (LRPFS), disease-free survival (DFS), and radiation-induced toxicity were analyzed.
RESULTS: Between 2010 and 2013, a total of 18 patients with 20 implants were enrolled and treated with surgical resection and brachytherapy for the management of locoregional recurrences of head and neck cancer. The majority of histology was squamous cell carcinoma (10 of 18). All but one patient had a history of prior radiation in the area of tumor recurrence. One patient had gross residual disease following surgical resection. Two patients underwent an additional surgical resection and brachytherapy implantation 2 months and 5 months later for local recurrence that developed outside of the treatment volume. A total of 13 patients had previous locoregional recurrence treated with surgical salvage therapy. The total dose following initial definite external beam radiation therapy (RT) ranged from 5,000 cGy to 7,000 cGy. Two patients developed grade 3 toxicity; no grade 4 or 5 complications were observed. With a median follow-up of 38 months (range: 1–44 mo), 11 patients developed another recurrence or progression of head and neck cancer. In 6 of these 10 cases, the failure was locoregional, and in 4 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. The median OS was 15 months, and median DFS was 11 months. The 6-, 12-, and 18-month OS rates in this study were 77%, 71%, and 45%, respectively. The 6-, 12-, and 18-month LRPFS rates in this study in patients were 69%, 62%, and 52%, respectively. The 6-, 12-, and 18-month DFS rates in this study were 57%, 45%, and 37%, respectively.
CONCLUSION: Compared with prior literature, our study shows comparable rates of survival with a decreased rate of radiation-induced toxicity.
LMFAO basher? please! times have changed i believe and Cesium-131 will succeed or be bought out for a high price to shelf the technology. I hope the former
In 1999, I announced in this column that Life Extension was setting up a medical center that would provide every single scientifically documented cancer therapy. We built and furnished a 4,400-square-foot medical center, but it could not even get off the ground.
One reason was that no matter how hard we tried to comply with the law, practicing comprehensive oncology was virtually impossible in the regulated environment imposed on physicians today.
The government has succeeded in suffocating medical innovation by erecting enormous bureaucratic barriers. Physicians with novel ideas who try to bypass today’s labyrinth of Byzantine rules risk not only their license to practice medicine, but also their personal liberty.
The chilling effects of government restrictions on medical advancement are nothing short of paralyzing. Why should any doctor today risk everything he has to provide patients with improved care?
Medical oncologists make big money setting up chemotherapy centers that provide only FDA-approved drugs. While the failure rate of these drugs is frighteningly high, chemo drugs are approved by the FDA and fully reimbursed by Medicare and most private insurance plans. Oncologists have no incentive to make heroic attempts to utilize novel cancer treatments, which insurance will not pay for and which the government and media condemn.
When Life Extension tried to hire medical oncologists to work at our medical center, they all were impressed with our innovative approaches to cancer treatment. None of them, however, was willing to risk his license or sacrifice his lucrative “chemotherapy bonuses” by prescribing the kinds of multimodal therapies we recommended. These oncologists did say that if we ever set up our facility, they would send their family members to us rather than expose them to the mainstream oncology they practice for a living.
It is not a new cancer study, it's a discussion of
new delivery modalities using Cesium-131 Brachytherapy
tri-cityheraldDOTcom / 2015/04/19/3519204 / isoray-medical-uses-hanford-inspiredDOThtml
26/27 patients with moderate to severe brain cancer were cancer free after 2 years. Non Small Cell Lung Cancer study was for stage 1 which is the 1st stage so i would assume that since the brain study involved a more severe cancer than this lung study the results will be higher possibly 97-98%
the difference between these 2 companies who were and currently being attacked by the same people is Dendreon was a drug company ho had to spend millions getting their drug to be approved by the FDA so the short attack damaged their company. IsoRay is already FDA approved and has $20M in cash and no debt. They have enough money to last the next 5 years so this short attack wont destroy the company and cause them to fall into Bankruptcy like it did with Dendreon
google title article was released 1 hr ago
Blue Star? are you Bud Fox?
bunch of freaking cry babies
Where does it say lung study was bad? Do you realize you are playing into the MMs and shorties hands.
news-medicaDOTnet / news / 20150427 / Men-who-receive-brachytherapy-more-likely-to-be-cancer-free-five-years-laterDOTaspx